Why the study?
Immunotherapies improve survival among cancer patients but can cause inflammation, adverse cardiac immune modulation, and cardiac failure up to five to ten years after treatment.
Does immunotherapy cause cardiotoxicity and cardiac failure in cancer patients?
Design
Review
Authors
Loading...
Cancer immunotherapy warrants cardiac surveillance for immune-mediated failure; leaves open precise incidence and management in prospective studies.
Does immunotherapy cause cardiotoxicity and cardiac failure in cancer patients?
Immunotherapy can cause late-onset cardiotoxicity, highlighting the need for innovative experimental models like hiPSC-CMs and organoids to identify biomarkers and develop non-toxic therapies.
Kumar et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: